BioVentrix, Inc. (BVXX)

BioVentrix Income Statement

Financials in millions usd. Fiscal year is January - December.

Year Ending	Dec 31, 2025	Dec 31, 2024
Selling, General & Admin	5.1	2.97
Research & Development	1.17	0.59
Other Operating Expenses	-6.26	0
Operating Expenses	0.01	3.56
Operating Income	-6.27	-3.56
Interest Expense (Income)	1.39	0.31
Other Expense (Income)	0.01	-0.02
Pretax Income	-7.67	-3.85
Net Income	-7.67	-3.85
Free Cash Flow	-5.81	-2.72
EBITDA	-6.23	-3.5
Depreciation & Amortization	0.05	0.05
EBIT	-6.28	-3.54

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).